Global Alpha Capital Management Ltd. Increases Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Global Alpha Capital Management Ltd. grew its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 5.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,900 shares of the company’s stock after purchasing an additional 2,160 shares during the period. Global Alpha Capital Management Ltd. owned approximately 0.09% of Pacira BioSciences worth $752,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in PCRX. China Universal Asset Management Co. Ltd. grew its holdings in Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after buying an additional 918 shares in the last quarter. Caitlin John LLC grew its holdings in shares of Pacira BioSciences by 1,850.0% in the fourth quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after purchasing an additional 1,776 shares in the last quarter. Nisa Investment Advisors LLC increased its position in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock worth $62,000 after purchasing an additional 2,749 shares during the last quarter. Quest Partners LLC raised its stake in Pacira BioSciences by 137.6% during the third quarter. Quest Partners LLC now owns 9,410 shares of the company’s stock valued at $142,000 after purchasing an additional 5,449 shares in the last quarter. Finally, Virtus Investment Advisers Inc. bought a new position in Pacira BioSciences during the third quarter valued at $98,000. 99.73% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have recently issued reports on PCRX shares. Royal Bank of Canada restated a “sector perform” rating and set a $18.00 target price on shares of Pacira BioSciences in a research report on Tuesday, January 14th. Truist Financial upgraded Pacira BioSciences from a “sell” rating to a “hold” rating and upped their price objective for the company from $8.00 to $25.00 in a research report on Thursday, January 30th. Needham & Company LLC lifted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, February 28th. Barclays increased their price target on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Finally, HC Wainwright lifted their price objective on shares of Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Stock Down 2.1 %

NASDAQ:PCRX opened at $23.37 on Friday. The company has a market cap of $1.08 billion, a price-to-earnings ratio of -11.51 and a beta of 0.86. Pacira BioSciences, Inc. has a twelve month low of $11.16 and a twelve month high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51. The stock has a fifty day simple moving average of $23.55 and a 200-day simple moving average of $18.94.

About Pacira BioSciences

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.